What questions do you have for the pioneers at Henry Ford, home of the world's first MRIdian Linac? With three years of patient treatments under their belts, they are experts on establishing and growing a MRIdian program, creating enough demand from patients and referring physicians to require the installation of a second system. Join Dr. Chetty for this engaging, interactive session.
Henry Ford Health System
Dr. Chetty is Professor and Division Head of Medical Physics in the Department of Radiation Oncology at Henry Ford Hospital, a position in which he has served since 2007. He oversees the operations for a large group of medical physicists (>30) working to provide routine clinical medical physics services, and actively engaged in research development. During his PhD at UCLA, Dr. Chetty specialized in the area Monte Carlo-based dose calculations for lung cancer. When he joined the University of Michigan in 2000, he developed a strong research track record in the area of dose calculations and motion management for patients with lung cancers. In 2005, he was awarded a NIH/NCI R01 grant to investigate correlations of dose with outcome for patients with lung cancers. He served as the Chair of the AAPM Task Group No. 105 on the use of Monte Carlo methods for radiotherapy dose calculations in 2007, and more recently has been actively engaged in the efforts of AAPM Task Group No. 157 on beam modeling for Monte Carlo dose calculations. Dr. Chetty has amassed a significant amount of experience in the area of dose calculations, motion management and image-guided radiation therapy (IGRT) and adaptive radiotherapy, including use of the MRgRT technology. Over the past 10 years his research has focused on investigation of technical aspects related to adaptive radiotherapy, focused as well on daily on-line ART using the low B field MRgRT machine. He is also involved in research pertaining to quantitative image analysis (in particular, radiomics) as well as the use of artificial and augmented intelligence for various tasks in radiotherapy, such as automated contouring. Dr. Chetty has published over 160 peer-reviewed articles and is Fellow of both ASTRO and AAPM.
Vice President of Clinical Marketing
Michael Saracen is Vice President of Clinical Marketing at ViewRay Inc., where he has worked since 2012 helping with the development, productization, and launch of the MRIdian and MRIdian Linac products into the commercial market globally. He has nearly 25 year’s experience with innovating, patenting, developing, and launching new products into the medical device industry. With over 18 years specifically focused on Radiation Oncology working for companies such as Radionics, CIVCO, and Accuray. Michael received his Masters from Brown University in Biomaterials and Artificial Organs and has 19 issued patents covering robotics, QA, tracking & vision systems, and treatment planning software.